BUND FINANCE › Stocks › NTRA
Natera, Inc. (NTRA)
NASDAQ · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 19, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is -23.17% below its 50-day average.
- It is +6.49% above its 200-day average (long-term uptrend).
- It sits at 42% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$625.5M | US$820.2M | US$1.1B | US$1.7B | US$2.3B |
| Net income | −US$471.7M | −US$547.8M | −US$434.8M | −US$190.4M | −US$208.2M |
| EPS (diluted) | -5.21 | -5.57 | -3.78 | -1.53 | -1.52 |
| Gross margin | 49.1% | 44.4% | 45.5% | 60.3% | 64.9% |
| Operating margin | -74.9% | -66.0% | -41.2% | -13.1% | -13.4% |
| Net margin | -75.4% | -66.8% | -40.2% | -11.2% | -9.0% |
| Free cash flow | −US$376.3M | −US$479.2M | −US$286.2M | US$69.2M | US$109.1M |
| Total debt | US$397.2M | US$446.2M | US$442.0M | US$187.1M | US$214.4M |
| Cash | US$84.4M | US$466.1M | US$642.1M | US$945.6M | US$1.1B |
Compound annual growth: revenue 38.6% · net income — (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | — | — | 26.4x |
| EV / EBITDA | — | — | 16.3x |
| Operating margin | -9.0% | — | 3.6% |
| Net margin | -5.7% | — | -0.0% |
| Debt / equity | 0.47 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Natera, Inc.
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited gen…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice